Morgan Stanley
CADL icon

Morgan Stanley’s Candel Therapeutics CADL Stock Holding History

Morgan Stanley’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
126,145
+67,916
+117% +$513K ﹤0.01% 5090
2026
Q1 		$285K Sell
58,229
-75,802
-57% -$413K ﹤0.01% 5718
2025
Q4 		$757K Buy
134,031
+58,090
+76% +$313K ﹤0.01% 5317
2025
Q3 		$387K Sell
75,941
-37,781
-33% -$218K ﹤0.01% 5616
2025
Q2 		$575K Buy
113,722
+51,246
+82% +$264K ﹤0.01% 5402
2025
Q1 		$353K Sell
62,476
-12,799
-17% -$105K ﹤0.01% 5488
2024
Q4 		$653K Buy
75,275
+10,842
+17% +$64.1K ﹤0.01% 5309
2024
Q3 		$447K Buy
64,433
+44,975
+231% +$279K ﹤0.01% 5457
2024
Q2 		$121K Buy
+19,458
New +$146K ﹤0.01% 5897
2023
Q1 		– Sell
-92
Closed -$165 – 7724
2022
Q4 		$165 Sell
92
-5,188
-98% -$10.3K ﹤0.01% 7658
2022
Q3 		$17K Buy
5,280
+659
+14% +$2.23K ﹤0.01% 6851
2022
Q2 		$15K Sell
4,621
-30
-0.6% -$120 ﹤0.01% 7091
2022
Q1 		$24K Sell
4,651
-71
-2% -$353 ﹤0.01% 7068
2021
Q4 		$36K Buy
+4,722
New +$45.8K ﹤0.01% 6961

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's CADL Position: Q2 2026 in Review

Morgan Stanley increased its Candel Therapeutics (CADL) stake by 117% in Q2 2026, buying an estimated $513K and bringing the position to 126,145 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #5090.

Morgan Stanley first reported a position in CADL in Q4 2021 and has held it in 14 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Morgan Stanley held 126,145 shares of Candel Therapeutics worth $1.3M as of Q2 2026.
  • Morgan Stanley bought 67,916 Candel Therapeutics shares in Q2 2026, an estimated $513K.
  • Candel Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5090 holding.
  • Morgan Stanley first reported a position in Candel Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.